Loading
Metastasis and Carcinoma Case Studies / Breast Lesions and Carcinomas · Journal article
Terapevticheskii Arkhiv · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a single case report of invasive lobular breast carcinoma (luminal A, T1N1M0) metastasizing to the small and large intestine, initially misdiagnosed as Crohn's disease over approximately 20 years based on imaging and elevated fecal calprotectin. The case illustrates the diagnostic challenge posed by diffusely infiltrative metastases and emphasizes the need for oncological vigilance and immunohistochemistry in atypical presentations of inflammatory bowel disease in patients with cancer history.
Clinical case report. Single 55-year-old female with 20-year history of abdominal pain syndrome, initially diagnosed with Crohn's disease based on imaging and elevated fecal calprotectin; one year after confirmation of invasive lobular breast cancer, developed dynamic intestinal obstruction requiring surgical interventi…. Intervention: Surgical resection of intestinal segment with histological and immunohistochemical examination.
55-year-old female with 20-year history of abdominal pain syndrome initially attributed to Crohn's disease Elevated fecal calprotectin levels supported the Crohn's disease diagnosis despite lack of response to standard therapy Invasive lobular breast cancer (luminal A subtype, T1N1M0) confirmed one year prior to identification of intestinal metastases
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should maintain oncological vigilance when evaluating patients with abdominal symptoms and a history of cancer, particularly when inflammatory markers are elevated but standard therapy for inflammatory bowel disease proves ineffective. Immunohistochemistry should be used to confirm the diagnosis of suspected inflammatory bowel disease in such high-risk patients.
A single clinical case report describing an unusual diagnostic presentation; raises awareness of a rare mimicry but provides no generalizable evidence about incidence, diagnosis, or management.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should maintain oncological vigilance when evaluating patients with abdominal symptoms and a history of cancer, particularly when inflammatory markers are elevated but standard therapy for inflammatory bowel disease proves ineffective. Immunohistochemistry should be used to confirm the diagnosis of suspected inflammatory bowel disease in such high-risk patients.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Invasive lobular breast carcinoma is characterized by infiltrative growth and a tendency toward atypical metastasis, including to the gastrointestinal tract, where metastases are often diffusely infiltrative, complicating their visualization and potentially leading to diagnostic errors. This paper presents a clinical case of a 55-year-old female patient with long-standing (approximately 20 years) abdominal pain syndrome. Based on imaging studies and elevated fecal calprotectin levels, this pain syndrome was interpreted as Crohn's disease, despite the lack of response to standard therapy. One year after confirmation of invasive lobular breast cancer (luminal A subtype, T1N1M0), the patient continued to experience abdominal symptoms until the development of dynamic intestinal obstruction, which required surgical intervention. Histological and immunohistochemical examination of the resected intestinal segment confirmed metastatic involvement of the small and large intestines. This case demonstrates a rare variant of lobular breast cancer metastasis to the intestine, which had been masquerading as Crohn's disease for a long time. It highlights the need for oncological vigilance in patients with abdominal symptoms and a history of cancer, as well as the crucial role of immunohistochemistry in verifying the diagnosis.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.